What question did this study set out to answer?

Assess long-term survival outcomes and correlative biomarkers of sequential pembrolizumab and AVD chemotherapy in patients with previously untreated classic Hodgkin lymphoma.

September 9, 2022Blood AdvancesOpen Access

Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma

View Full Paper

Ask AI

Bookmark

Authors

PAPamela B. AllenEmory University XLXinyan LuNorthwestern University QCQing ChenHainan University

Discussion

Member takes

Implication

Phase 2 trial demonstrates 100% survival with sequential pembrolizumab and chemotherapy in untreated classic Hodgkin lymphoma, indicating efficacy regardless of PD-L1 levels.

Key Points

Assess long-term survival outcomes and correlative biomarkers of sequential pembrolizumab and AVD chemotherapy in patients with previously untreated classic Hodgkin lymphoma.
Multicenter phase 2 clinical trial involving 30 patients (N=30) with untreated, unfavorable, or advanced-stage classic Hodgkin lymphoma.
Patients received 3 cycles of pembrolizumab monotherapy followed by 4 to 6 cycles of AVD chemotherapy, with PET/CT response assessments throughout.
Analyzed baseline biopsy samples for 9p24.1 genomic alterations and PD-1 pathway markers over a median follow-up of 33.1 months (range, 26.0–43.0).
Progression-free survival and overall survival remained at 100% at a median follow-up of 33.1 months.
All patients (100%) exhibited 9p24.1 alterations and tested positive for PD-L1 expression via immunohistochemistry.
Depth of response to single-agent pembrolizumab showed no significant relationship with 9p24.1 alterations or PD-1 pathway H-scores.

Cite This Study

Allen et al. (2022) studied this question.

synapsesocial.com/papers/6aa930f9d0c7c778ac8cbbb8 https://doi.org/10.1182/bloodadvances.2022008116

View Full Paper

Ask AI

Bookmark

Implication

Phase 2 trial demonstrates 100% survival with sequential pembrolizumab and chemotherapy in untreated classic Hodgkin lymphoma, indicating efficacy regardless of PD-L1 levels.

Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider